Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
It was quite strange, because at 7am it was showing 2 RNSs but I could find nothing on LSE. Then they disappeared and reappeared later in the morning! The problem seems to be the double listing with TYR, but I am also registered for email alerts and didn't receive one this morning. Did anyone else?
appears on the TYR thread
Disappointing to see that LSE can't keep up to date with RNS releases. Another one released today with no indication on this site. ADMIN please sort it out. Thanks in advance
Hi Fluralaner comes from a new class of drugs approved about 3 years ago and they have taken the market for flea tick control in SA. This is from Merck &Co(Intervet/MSD) and they are big in LIvestock and obviously see application there but whilst they will do mites and ticks(both have GABA CNS) but flies are different. The big appeal of Tyratech is being effective but also more natural.The farmers etc will use cheap and effective but consumer pressure may well benefit TYRU technology
Agreed pwak ,although the new solutions for dealing with red mite infestations in poultry can only serve to crowd out,to some extent,Tyratech's PureScience products. The TYRU BOD have acknowledged that there is strong competition out there but feel that the market place is diversified enough to accommodate more than one approach.
Thanks for that Luke, the poultry farmers and suppliers must now about this and you would think be looking for a safer alternative. Information like this would be detrimental to the poultry industry and a non toxic spay like Tyratechs would be far better !!!
http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits_-_Report/2017/02/WC500221753.pdf ivyspivey mentioned the new approaches for controlling ticks etc. It is no wonder that the quality of our food chain is nowadays so suspect when one reads the implications of these treatments. It is also worth noting that the run off from poultry operations utilising this chemistry is highly toxic for aquatic life. Radio active chicken livers ? No more pate for me thanks.
2.2.1. Pharmacokinetics in target species Fluralaner is well absorbed in laying hens, with an oral bioavailability of 91% (after oral gavage). When fluralaner was administered via the drinking water at a dose rate of 0.5 mg/kg bw to laying hens, repeated after 7 days, the Cmax was 323.7 ng/ml (at tmax 36 hours) and 355.1 ng/ml (at tmax 12 hours) respectively after first and second administration. The AUC was calculated to be 1297 ng.day/ml after the first administration (from time 0 to day 7) and 2388 ng.day/ml after the second administration (from day 7 to infinity), indicating accumulation of fluralaner. When administered at a single oral dose of 0.25, 0.5 and 1 mg fluralaner/kg bw, it was demonstrated that the Cmax (respectively 326.2, 599.7 and 1301.6 ng/ml) and AUCinf (1317.5, 2249.9 and 4581.7 ng.day/ml) were proportional to the applied dose. R- and S-enantiomers of fluralaner were shown to display similar pharmacokinetic profiles. The plasma half-life of fluralaner in chickens, determined after intravenous administration was about 5 days. A radiolabelled residue study administering [14C]-fluralaner at two single doses of 0.5 mg fluralaner/kg bw, 7 days apart by oral gavage demonstrated that a large portion of the total dose is excreted via eggs, i.e. a mean of 28.8% of total dose. Excreta were not collected, though fluralaner and/or metabolites were measured at high concentrations in bile (mean of 15140 - 4690.30 µg equivalents/kg at 24 - 168 hours after administration). Highest concentrations of total radioactive residues (TRR) in tissues were observed in liver followed by skin and fat, kidneys and muscle. Mean TRR levels in liver were 1479 μg equivalents/kg at 12 hours after the last administration decreasing to 337 μg equivalents/kg at 168 hours after the last administration. Mean TRR levels in kidney were 1091 μg equivalents/kg at 12 hours after the last administration decreasing to 248 μg equivalents/kg at 168 hours after the last administration. Mean TRR levels in muscle were 211 μg equivalents/kg decreasing to 48 μg equivalents/kg at 168 hours after the last administration. Mean TRR levels in skin and fat were 1118 μg equivalents/kg at 12 hours after the last administration decreasing to 319 μg equivalents/kg at 168 hours after the last administration. The major component detected in all tissues was fluralaner. Fluralaner concentrations were additionally measured by LC-MS/MS in this study. In eggs, the TRR concentrations increased following the first dose administration, reaching a maximum (average) of 737.31 μg fluralaner equivalents/kg on day 7. The TRR concentrations then decreased before increasing to a (average) maximum of 939.80 μg fluralaner equivalents/kg on day 13. From day 13, TRR concentrations decreased down to a minimum of 200.52 μg fluralaner equivalents/kg on day 22. The major component detected in whole eggs was fluralaner. Flur
Without doubt,Tyratech and its IP is currently the subject of much scrutiny. Across at Mondelez,following the release of its 2016 accounts,CEO Irene Rosenfeld highlighted the company's strategy to focus its portfolio.This coincided with the retirement of Dr Abraham Senior Vice Presidente Research and Nutrition who was responsible for the joint development of the Tyratech IP. (Dates EmployedMar 2000 – Feb 2017 Employment Duration17 yrs Just retired - February 3, 2017.) Interestingly TYRU and Mondelez are highlighted in this USAID document (at Annex VI),being a Summary of the Parasite Protection Food Technology Meeting in Washington DC Sixteen participants were part of the discussion, including Mr. Matt Nims, Deputy Director of USAID/FFP; Dr. Todd Abraham, Sr. Vice president for Mondelēz; Dr. Irwin Rosenberg, former Dean of the Tufts University School of Nutrition and Professor Bruno Jactel, CEO of TyraTech, as well as other experts from each participating organization (USAID, Mondelēz, Tyratech, Tufts University, and the National Institute of Health). http://pdf.usaid.gov/pdf_docs/PA00KNBK.pdf If Tyratech's patented anthelmintic technology can be monetized alongside the successful expansion of its animal health ranges,not to mention the EBITDA positive Vamousse division,then shareholders might well be rewarded for their patience.imo.
1University of Georgia, Department of Infectious Diseases, College of Veterinary Medicine, Athens, GA 30602, USA. Electronic address: r******@uga.edu. 2University of Georgia, Department of Infectious Diseases, College of Veterinary Medicine, Athens, GA 30602, USA. 3George Mason University, Department of Statistics, Fairfax, VA, USA. 4TyraTech Inc., Morrisville, NC, USA. 5University of Georgia, Department of Population Health, Athens, GA, USA. 6Kraft Foods, Northfield, IL, USA. Abstract Ascaris lumbricoides is the most prevalent soil-transmitted helminth (STH) infection of human beings worldwide. Chemotherapy with synthetic anthelmintics such as albendazole, mebendazole, and pyrantel pamoate is the current method of treatment; however, the emergence of anthelmintic resistance could substantially decrease the efficacy of such treatments and the sustainability of STH control programs. Additionally, benzimidazoles are not recommended for pregnant women or children under age one. A blinded, controlled study was conducted to evaluate the efficacy of two microencapsulated, plant-based essential oil blends, TTN1013 (α-pinene, linalyl acetate, p-cymene, and thymol octanoate) and TTN1014 (α-pinene, linalyl acetate, p-cymene, and thymol acetate) as functional foods against Ascaris suum infection in pigs, an important pathogen that closely resembles human infections with A. lumbricoides. Four groups of 16 female, 21-24 day old, Yorkshire-cross pigs were treated daily with 0.5 or 1.0mg/kg TTN1013, 1.0mg/kg TTN1014, or 1.0mg/kg equivalent of empty capsules, delivered inside a cream-filled sandwich cookie for 14 weeks. Three days after the initiation of daily treatments, pigs were inoculated daily with A. suum eggs for four weeks. Pigs were weighed weekly and fecal egg counts (FEC) were conducted weekly starting five weeks after initial inoculation with A. suum eggs. Fourteen weeks after first infection with eggs, pigs were necropsied and worms were recovered, counted and separated according to sex. TTN1013 administered daily at a dose of 1.0mg/kg yielded a statistically significant reduction in total worm counts (76.8%), female worm counts (75.5%), FEC (68.6%), and worm volume (62.9%) when compared to control group. Reduction of total and female worm numbers and FEC were not significant for TTN1014 or at the 0.5mg/kg dose of TTN1013. All treatments were well-tolerated by all pigs and did not cause any adverse reactions. All pigs remained clinically normal and showed no signs of reduced intestinal health for the duration of treatment. Based on these results, TTN1013 shows promise as a daily supplement to reduce infection burdens of soil transmitted helminths in both pigs and human beings.
for providing such knowledgeable input. I look forward to your additional comments as matters progress.
Hi The IP with Mondelez states anthelmintics which basically means wormers or internal parasites so they are looking at human products and although anthelminticsvare extensively used in farm animals fleas and ticks are external parasites and yes the TYRU technology will work vs these but not this particular IP. The expertise of the BOD is with external parasites and there are very effective products in both large and small animal including new chemistry afoxalana and flurolana which incidentally I will be selling in the near future. All my previous experience was with the avermectins and fipronil which was internal/e thermal in livestock/horses and pets so I know this space reasonably well
The very same pwak except that Kraft became Mondelez following the offloading of its grocery arm. Taken from the latest TYRU Interim statement :- "Collaborative revenue remained steady at $164,000 (2015: $167,000). Collaborative revenue includes upfront license fee amortisation and cost reimbursement from our Envance Technologies and Mondelez Global (Kraft) agreements. " The fact that Mondelez/Tyratech are now seeking to out license the technology could have radical implications for TYRU,particularly if,as seems to be the case, the whole sweep of the the Tyratech IP looks to be on offer.
Would this be the technology they produced originally in partnership with Kraft foods ?
Fantastic development, and bear in mind Tyratech have proof of concept on a whole host of goodies including fleas & ticks in companion animals, another BIGGIE !!
What do you make of the list of IP available for licensing ivyspivey. Could it represent the whole animal health side ?
Thanks ivyspivey Global corporate Mondelez International (Market Cap US$ 66 BILLION with over 100,000 employees)and micro cap Tyratech jointly develop and design a safe, natural and non-toxic solution for intestinal parasites that is deployable as a daily maintenance solution through several platforms and has potential applications for both human and animal health applications.. "High value technology solution" "Proprietary breakthrough technology" You couldn't make this up !
This is interesting for TYRU investors. Global corporate Mondelez and tiny Tyratech seek to license TYRU technology. https://ninesights.ninesigma.com/web/mondelez-international-gallery/needs-listing/-/needs-portlet/viewNeed?_NeedsPortlet_WAR_NeedPortletsportlet_needId=644 The closing date is later this month. VERY INTERESTING imo.
Corner turned
Useful input chart wise Crucial thing to me is at which point it becomes profitable.That is when the corne Vuillard be well and truly changed imo
BIKWIK a chartist posting on ADVFN favoured us with a look at TYRU,noting that:- "There are three clear cycles on the chart, each about a year in duration. The cycles end either at or towards the end of each year. Given that the trend in these three cycles is down one could be forgiven for expecting the next cycle to be down as well. Given the angle of overall descent that would suggest the share price was destined to reach zero or the company goes bust. However, don't panic! After the third cycle a change often occurs. So, as the company looks pretty healthy (cash of $1.7m plus at the int stage...I checked), though maybe it has eaten into that a little bit by the Dec 2016 year end as its not making a profit yet. I digress from the chart! So, it seems to me that the recent lows - all six of them! - look like the bottom. We should be commencing an upswing phase. At this stage it looks early days and 2p, maybe just under, could be retested, though encouragingly the volume last week on the move up to 2.5p was the highest in over 5 months. There is an important downtrend line shown - currently around 3p. This needs to be cleared to suggest the trend was starting to turn to the upside and thus be sustainable. The 40 week (200 day) moving average - currently falling also needs to start rising to confirm such an upward shift was occurring. Clearing the resistance at 3.50p would be excellent news but I think you may have to be patient a bit longer, though as I said I think the low is in. Good luck." The SP upturns were seen starting in late February through until mid May with a steady decline setting in thereafter. If this trend is continued in 2017 we could be looking at a rising SP at any moment. A positive news flow from Tyratech could then ensure further progress throughout the full year.
Helps explain action of Tyramine which is obviously Tyratech technology hence the name but does not explain actual way it blocks the neurotransmitters. Normally the drugs that kill parasites would block the chlorine channels of anything that would have say a GABA Neurotransmitter system such as fleas and ticks and would effectively stop their development at her than repelling.
ivyspivey-I don't know if this is relevant,but I cobbled it together from various sources over the weekend. Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with two or more hetero atoms five-membered rings. Tyramine receptors belong to the Class A GPCR family. In mammalian systems, tyramine is a member of the trace amines, but in insects octopamine and tyramine are thought to be the main neurotransmitters. Dr.Essam Enan discovered,patented and assigned the technology to Tyratech. Embodiments of the present invention provide compositions for controlling a target pest including a pest control product and at least one active agent, wherein: the active agent can be capable of interacting with a receptor in the target pest; the pest control product can have a first activity against the target pest when applied without the active agent and the compositions can have a second activity against the target pest; and the second activity can be greater than the first activity. "Dr. Enan’s scientific research discoveries and breakthroughs have had significant impact on the industry. In 1996, Dr. Enan’s discovery of octopamine receptor as a target for some plant essential oils helped the business of a pesticide company producing natural insecticides in making and selling more effective products. In 2003, Dr. Enan’s screening platform was successfully created, established and used to identify and develop synergistic blends of plant essential oils with potent insecticidal activity. This groundbreaking work led directly to the creation of another pesticide company in April 2004, which went public on the London Stock Exchange (AIMS) in 2007. Dr. Enan is passionate about providing environmentally safer and all natural products that will drastically improve the quality of life for animals, plants, and humans, and has spent his career perfecting his science and inventions to achieve this goal. "
So the tick activity is a repellency like all synthetic pyrethrums.Presume fly activity is similar and that works really well in livestock/equine.Does anyone know if flea activity of any of technology is contact or repellency
Love the video lukehere. Thanks for posting.